
Single-cell omics and Al-fueled discovery to help endometriosis patients
Single-cell omics and Al-fueled discovery to help endometriosis patients
Scailyte’s powerful single-cell AI platform, ScaiVision, has played a pivotal role in a groundbreaking move in the field of endometriosis. Hera Biotech is set to acquire and bring to the patients Scailyte’s endometriosis diagnostic assets, marking a significant milestone in non-surgical diagnosis of endometriosis.
Leveraging the biggest single-cell RNAseq dataset in endometriosis and our best-in-class biomarker discovery platform, ScaiVision, we have identified highly accurate biomarkers for the diagnosis of endometriosis. Unlike conventional methods for analysis and interpretation of single-cell data that start with cell clustering and cell type annotation, ScaiVision is using an unbiased representation learning method that allows ultra-sensitive discovery of novel biology.
Following the discovery of the disease-associated gene signatures and cell phenotypes from single-cell data, we went through several translational steps and prototyped a conventional and scalable qPCR assay, which Hera Biotech will now validate further and deploy in clinical laboratories in the USA.
Reach out if you want to learn more about ScaiVision and how we can partner to make groundbreaking discoveries leveraging multi-omics data and our proprietary AI platform!
In a stride towards non-surgical endometriosis diagnosis, Hera Biotech has announced its impending acquisition of endometriosis diagnostic assets from Scailyte, a company active in single-cell and AI-driven biomarker discovery. This acquisition marks a notable consolidation in the tissue-based diagnostic landscape for endometriosis, a prevalent condition contributing to a significant portion of female infertility and characterized by severe pain due to the abnormal growth of uterine-like tissue outside the uterus.
Standard diagnosis methods involve invasive laparoscopic surgery, leading to delayed diagnosis. However, the collaborative research between Hera Biotech and Scailyte, along with their academic partners, has led to the development of complementary biomarkers and assays, presenting a more direct, accurate, and non-invasive diagnostic approach. This consolidation is expected to speed up the creation of clinical tools for diagnosing and stratifying endometriosis patients and facilitate the development of targeted therapies.
Scailyte CEO, Dr. Peter Nestorov, commented: “We are excited to work with Hera to integrate Scailyte’s endometriosis assets into the Hera pipeline. Through our collaboration with Prof. Michael Mueller from the University of Bern, we have generated the largest single-cell RNAseq datasets from peripheral blood and endometrial tissue. The insights we gained clearly indicate that the tissue-based approach is the only way to capture the complexity and heterogeneity of endometriosis, and therefore tissue-based molecular assays will be the only viable alternative to laparoscopy for a definitive diagnosis and patient stratification.”
The initial product in the combined portfolio utilizes Scailyte’s deep sequencing discovery platform, promising a highly specific and robust diagnostic assay for endometriosis. Hera Biotech aims to launch this product in the US fertility market by late 2024, followed by another product for the definitive diagnosis and staging of endometriosis in the OB/GYN market.
“We are delighted that this partnership also affords Hera the opportunity to add Dr. Cinzia Donato to our executive team and Professor Michael Mueller to our scientific advisory board. Dr. Donato and Professor Mueller were the driving forces behind Scailyte’s endometriosis diagnostic program and bring a breadth of scientific and commercial skills to complement Hera’s in-house diagnostic programs. We are excited to announce this partnership in conjunction with our $15M Series A raise, which we are kicking off at the JP Morgan Healthcare conference next week,” said Somer Baburek, CEO Hera Biotech.
The transaction is expected to be finalized by the end of January 2024, post the completion of due diligence.
About Scailyte
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.
Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
Recent News
Scailyte is fundraising!
Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...
Recent News
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Recent News
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
Recent News
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...
Recent News
Scailyte is fundraising!
Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...
Recent News
Precision Medicine and The Future of Genomics Summit 2024
Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...
Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution
In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...
Recent News
Pitch Nic 2024 at Novartis Campus
We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...
Recent News
Genomics for Health 2024
Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...
The Year of the AI Nobel
2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...